Abstract
Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently occurs with atopic comorbidities, including allergic rhinitis (AR). Dupilumab inhibits signaling of interleukin (IL)-4 and IL-13 – key drivers of type 2-mediated inflammation in multiple diseases, including AD and AR. This subgroup analysis evaluated the efficacy of dupilumab with concomitant topical corticosteroids (TCS) for severe AD in children with and without comorbid AR.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
